Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, Falkencrone S, Brand J, Kromminga A, Hawro T, Church MK, Maurer MJ. Allergy Clin Immunol. 2017 Mar; 139(3):1059-1061.
Access Here
Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative study.
Wadhwa M, Mytych DT, Bird C, Barger T, Dougall T, Han H, Rigsby P, Kromminga A, Thorpe R; Participants of the Study. J Immunol Methods. 2016 Aug; 435:32-42.
Access Here
Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a Phase 1 study.
Curtin F, Vidal V, Bernard C, Kromminga A, Lang AB, Porchet H. MAbs. 2016 Mar 30:0. [Epub ahead of print]
Access Here
B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera.
Homann A, Röckendorf N, Kromminga A, Frey A, Jappe U. J Transl Med. 2015 Oct 29; 13:339. doi: 10.1186/s12967-015-0706-7.
Access Here
Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.
Curtin F, Perron H, Kromminga A, Porchet H, Lang AB. MAbs. 2015;7(1):265-75. doi: 10.4161/19420862.2014.985021.
Access Here
Services
Platforms